Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Inhibikase Therapeutics announced the sale of 25 million shares through its at-the-market facility, raising $50 million gross. The capital is intended to support operations through topline data readout of Part B of its global Phase 3 IMPROVE-PAH trial evaluating IKT-001 for Pulmonary Arterial Hypertension. The transaction involved RA Capital Manage…